Viktor Grünwald

43PUBLICATIONS
214CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Oct 24, 2026
Improving Patient Access to New Treatment Modalities in European Cancer Care.

|Sep 29, 2026
[Current Systemic Therapy of Metastatic Renal Cell Carcinoma].

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Jul 28, 2026
Impact of COPD on Outcomes After Pulmonary Metastasectomy: A Propensity-Score Matched Analysis.

|Jul 18, 2026
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).

|Jul 15, 2026
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

Pageof 8

Frequent Collaborators

4 joint publications

Michael Hölzel

4 joint publications

Phillipp Ivanyi

4 joint publications

Martin Schuler

4 joint publications

Sebastian Bauer